We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+8.59%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$102M
AUM Growth
-$835K
Cap. Flow
-$2.14M
Cap. Flow %
-2.1%
Top 10 Hldgs %
58.99%
Holding
87
New
21
Increased
24
Reduced
14
Closed
28

Top Buys

Rank Stock Value
1
VSTM icon
Verastem
VSTM
+$4.68M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.45M
3
ARDX icon
Ardelyx
ARDX
+$2.29M
4
ALMS
Alumis Inc
ALMS
+$1.65M
5
ITOS
iTeos Therapeutics
ITOS
+$1.61M

Top Sells

Rank Stock Value
1
OPTN
OptiNose
OPTN
+$7.23M
2
URGN icon
UroGen Pharma
URGN
+$3.69M
3
AQST icon
Aquestive Therapeutics
AQST
+$3.04M
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$2.36M
5
ESTA icon
Establishment Labs
ESTA
+$2.35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTX icon
76
Nkarta
NKTX
$152M
– –
-10,000
Closed -$18.4K
OPTN
77
DELISTED
OptiNose
OPTN
– –
-788,647
Closed -$7.23M
PROF
78
Profound Medical
PROF
$263M
– –
-139,942
Closed -$814K
PYPD icon
79
PolyPid
PYPD
$78.2M
– –
-54,975
Closed -$149K
RNXT icon
80
RenovoRx
RNXT
$40.5M
– –
-278,188
Closed -$275K
SCPH
81
DELISTED
scPharmaceuticals
SCPH
– –
-347,687
Closed -$914K
SLRN
82
DELISTED
ACELYRIN
SLRN
– –
-167,580
Closed -$414K
THRD
83
DELISTED
Third Harmonic Bio
THRD
– –
-212,783
Closed -$738K
URGN icon
84
UroGen Pharma
URGN
$1.97B
– –
-333,400
Closed -$3.69M
XGN icon
85
Exagen
XGN
$105M
– –
-95,747
Closed -$344K
SEPN
86
Septerna Inc
SEPN
$1.51B
– –
-68,084
Closed -$394K
WHWK
87
Whitehawk Therapeutics
WHWK
$181M
– –
-46,698
Closed -$83.1K
1 2 3
4

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return

Stonepine Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Stonepine Capital Management held 87 positions worth $102M, down 0.81% from $103M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Stonepine Capital Management's Q2 2025 filing shows 21 new, 24 increased, 14 reduced and 28 closed positions. Its largest new stake was Ardelyx: 555,000 shares worth $2.18M. The largest sale was OptiNose, an estimated $7.23M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

  • Stonepine Capital Management's largest Q2 2025 buy was Ardelyx: 555,000 shares worth $2.18M.
  • Stonepine Capital Management added most to Verastem in Q2 2025, an estimated $4.68M increase.
  • Stonepine Capital Management's biggest Q2 2025 reduction was Establishment Labs, cutting an estimated $2.35M.
  • Stonepine Capital Management fully exited OptiNose in Q2 2025, selling an estimated $7.23M.
  • Stonepine Capital Management's ten largest holdings make up 59% of its $102M portfolio in Q2 2025.
  • Stonepine Capital Management opened 21 new positions and closed 28 in Q2 2025.
  • Stonepine Capital Management's portfolio value fell 0.81% quarter-over-quarter to $102M.

Based on Stonepine Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.